Pegylated interferon α-2b add-on to nucleos(t)ide analogues reduces hepatocellular carcinoma and decompensation in advanced fibrotic chronic hepatitis B

doi:10.3748/wjg.121641

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 45

This Article

(0)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 7, 2026; 32(45): 121641
Published online Dec 7, 2026. doi: 10.3748/wjg.121641

Full Size Figure Download Figure

Figure 4 Survival analysis stratified by mREACH-B model risk score: Nucleos(t)ide analogue monotherapy vs pegylated interferon α-2b combined with nucleos(t)ide analogues. A: Low-risk group (mREACH-B score 0-9), endpoint: Hepatocellular carcinoma; B: Low-risk group (mREACH-B score 0-9), endpoint: Decompensated cirrhosis; C: High-risk group (mREACH-B score 10-16), endpoint: Hepatocellular carcinoma; D: High-risk group (mREACH-B score 10-16), endpoint: Decompensated cirrhosis. HCC: Hepatocellular carcinoma; DC: Decompensated cirrhosis; HR: Hazard ratio; NA: Nucleos(t)ide analogue; Peg-IFNα-2b: Pegylated interferon α-2b.

Citation: Li XY, Huang JT, Liu T, Li YY, Zhe L, Cao H, Lin BL. Pegylated interferon α-2b add-on to nucleos(t)ide analogues reduces hepatocellular carcinoma and decompensation in advanced fibrotic chronic hepatitis B. World J Gastroenterol 2026; 32(45): 121641
URL: https://www.wjgnet.com/1007-9327/full/v32/i45/121641.htm
DOI: https://dx.doi.org/10.3748/wjg.121641

Li XY, Huang JT, Liu T, Li YY, Zhe L, Cao H, Lin BL. Pegylated interferon α-2b add-on to nucleos(t)ide analogues reduces hepatocellular carcinoma and decompensation in advanced fibrotic chronic hepatitis B. World J Gastroenterol 2026; 32(45): 121641 [DOI: 10.3748/wjg.121641]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.